NTS-104
Acute Ischemic Stroke (AIS)
Key Facts
About NeuroTrauma Sciences
NeuroTrauma Sciences is a private, pre-revenue biotech advancing small molecule therapies for stroke, a condition with significant unmet medical need beyond the current standard of care. The company's lead asset, NTS-104, is in Phase 1 development with data expected in 2025, targeting both acute and chronic stroke indications. Led by a seasoned team with deep expertise in neuroscience drug development and commercialization, NTS aims to transform stroke treatment by addressing neuroinflammation and promoting recovery. The company's strategy leverages a focused pipeline and experienced leadership to navigate the high-risk, high-reward neurology therapeutics landscape.
View full company profileAbout NeuroTrauma Sciences
NeuroTrauma Sciences is a private, pre-revenue biotech advancing small molecule therapies for stroke, a condition with significant unmet medical need beyond the current standard of care. The company's lead asset, NTS-104, is in Phase 1 development with data expected in 2025, targeting both acute and chronic stroke indications. Led by a seasoned team with deep expertise in neuroscience drug development and commercialization, NTS aims to transform stroke treatment by addressing neuroinflammation and promoting recovery. The company's strategy leverages a focused pipeline and experienced leadership to navigate the high-risk, high-reward neurology therapeutics landscape.
View full company profileOther Acute Ischemic Stroke (AIS) Drugs
| Drug | Company | Phase |
|---|---|---|
| TGD001 | TargED Biopharmaceuticals | Preclinical |
| DM199 (rinvecalinase alfa) | DiaMedica Therapeutics | Phase 2/3 |